D-Wave Quantum agreed to an award of up to $100,000,000 under the U.S. CHIPS and Science Act, with funding tied to specified project milestones. The anticipated issuance of 7,095,721 common shares at $14.093 per share is expected to dilute existing stockholders, while government ownership may constrain future strategic transactions.
Key Highlights
- The Department will make an initial $53,552,620 funding Tranche available shortly after the Award Date.
- D-Wave Quantum will issue 7,095,721 common shares to the Department at $14.093 per share.
- The agreement gives the U.S. government intellectual-property rights for funded inventions and permits remedies including termination for non-compliance.
Milestone Funding and Equity Terms
The U.S. Department of Commerce will make $53,552,620 available shortly after September 4, 2026. Additional payments of $9,075,000, $16,695,000, $20,390,000 and $287,380 will follow as specified milestones are reached. Those milestones include equipment installation, quantum processing unit prototypes, process integration, and the calibration and benchmarking of scaled units.
D-Wave Quantum (NASDAQ: QBTS) will issue 7,095,721 common shares with a $0.0001 Par Value at $14.093 per share. That price reflects a 15% discount under the pricing formula. The shares will be unregistered, and transfer limits, a $1.00 repurchase right in certain termination circumstances and restricted voting rights will apply.
Government Funding Carries Stated Risks
The timing and amount of funding depend on the agreement’s conditions, available U.S. government appropriations and executive-branch support. Changes in law, regulation or federal policy could affect the funding or alter D-Wave Quantum’s obligations. Legal or administrative challenges could do the same.
The anticipated equity issuance is expected to dilute existing stockholders. In addition, the Department’s ownership and contractual registration rights may limit future strategic transactions. The company also said that unresolved financial, tax and accounting treatment could result in additional costs, charges, losses or changes to reported results.






Please wait processing your request...